Genting Xinyao B (01952) rose more than 6% in the intraday period, with a cumulative increase of more than 20% this week. As of press release, it rose 4.1% to HK$26.65, with a turnover of HK$87.213,400.
The Zhitong Finance App learned that Genting Xinyao B (01952) rose more than 6% intraday, with a cumulative increase of more than 20% this week. As of press release, it rose 4.1% to HK$26.65, with a turnover of HK$87.213,400.
According to the news, recently, Vertex Pharmaceuticals announced that it will acquire Alpine at a price of 65 US dollars per share for a total of about 4.9 billion US dollars, making it the largest acquisition in the biomedical field so far this year; in June of last year, Novartis purchased Chinook Therapeutics for 3.5 billion US dollars.
According to reports, there are only two drugs approved for IgA nephropathy in the world, namely budesonide delayed-release capsules (Tolifucan) from Genting Xinyao and Calliditas and travere's spasentane tablets (TRAVERE). According to Sullivan's data, the global autoimmune disease drug market is expected to reach 176 billion US dollars by 2030, with a compound annual growth rate of 3.6% from 2022 to 2030. Among them, the Chinese market is expected to reach nearly 25 billion US dollars in 2030, a tenfold increase compared to 2020, and is an important source of growth for self-immune drugs around the world.